Clinical Trial Update: Safety and Efficacy Study of a Triplet Combination of MLN9708, Lenalidomide and Dexamethasone in the Initial Management of Multiple Myeloma (IFM2013-06) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating a triplet regimen (MLN9708, Lenalidomide, Dexamethasone) for newly diagnosed multiple myeloma; study completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• DEXAMETHASONE (Dexamethasone)
• Lenalidomide (lenalidomide)
• MLN9708 (ixazomib)

Snippet

Sponsor: Nantes University Hospital | Conditions: Newly Diagnosed Multiple Myeloma | Phase 2 | Status: COMPLETED